Published in Hospital Law Weekly, March 18th, 2004
Three patients injected with the vaccine, GVAX, had no recurrence of lung cancer for more than 3 years afterward, according to the study of 43 people with the most common form of the disease, non-small-cell lung cancer.
The findings were published in theJournal of the National Cancer Institute. The research was funded in part by CellGenesis, a pharmaceutical company that hopes to produce the vaccine.
The vaccine, developed by researchers at Baylor University Medical Center in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.